

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) A composition comprising an oligopeptide 13 residues or less in length, which comprises the sequence ATLERTEVY (SEQ ID NO:31040).
2. (Previously presented) A composition of claim 1, wherein the oligopeptide is joined to an amino acid linker.
3. (Previously presented) A composition of claim 1, wherein the oligopeptide is admixed or joined to a CTL epitope.
4. (Previously presented) A composition of claim 1, wherein the oligopeptide is admixed or joined to an HTL epitope.
5. (Original) A composition of claim 4, wherein the HTL epitope is a pan-DR binding molecule.
6. (Previously presented) A composition of claim 1, further comprising a liposome, wherein the oligopeptide is on or within the liposome.
7. (Previously presented) A composition of claim 1, wherein the oligopeptide is joined to a lipid.
8. (Previously presented) A composition of claim 1, wherein the oligopeptide is a heteropolymer.

9. (Previously presented) A composition of claim 1, wherein the oligopeptide is a homopolymer.

10. (Previously presented) A composition of claim 1, wherein the oligopeptide is bound to an HLA heavy chain, β 2-microglobulin, and strepavidin complex, whereby a tetramer is formed.

11-13. (Canceled)

14. (Previously presented) A composition comprising one or more peptides, and further comprising at least two oligopeptides 13 residues or less in length, wherein the first oligopeptide comprises the sequence ATLERTEVY (SEQ ID NO:31040); and

wherein each of said one or more peptides comprise less than 50 contiguous amino acids of a native peptide sequence of human papilloma virus (HPV) strains 16, 18, 31, 45, 33, and 56.

15. (Previously presented) A composition of claim 14, wherein one peptide comprises the at least two oligopeptides.

16. (Original) A composition of claim 14, wherein at least one of the one or more peptides is a heteropolymer.

17. (Original) A composition of claim 14, wherein at least one of the one or more peptides is a homopolymer.

18. (Previously presented) A composition of claim 14, further comprising an additional oligopeptide.

19. (Previously presented) A composition of claim 18, wherein the additional oligopeptide is derived from a tumor associated antigen.

20. (Previously presented) A composition of claim 18, wherein the first oligopeptide is joined to a cytotoxic T lymphocyte (CTL) epitope.

21. (Previously presented) A composition of claim 18, wherein the first oligopeptide is joined to a helper T lymphocyte (HTL) epitope.

22. (Original) A composition of claim 21, wherein the HTL epitope is a pan-DR binding molecule.

23. (Previously presented) A composition of claim 14, further comprising a liposome, wherein the first oligopeptide is on or within the liposome.

24. (Previously presented) A composition of claim 14, wherein the first oligopeptide is joined to a lipid.

25-27. (Canceled)

28. (Original) A composition of claim 14, further comprising an additional peptide admixed with the one or more peptides.

29. (Original) The composition of claim 28, wherein the additional peptide comprises a CTL or HTL epitope.

30-37. (Canceled)